Gallstones After Liver Transplant: Risks, Management & Prevention

Incidence and timing of gallstones post‑transplant

Gallstones are a known complication after orthotopic liver transplantation (OLT). They can form in the recipient's native gallbladder (if still present) or within the donor bile ducts (intrahepatic or extrahepatic).

• Incidence: 5‑15% within 5 years post‑transplant (higher in some series, up to 20%).
• Timing: Most present within the first 12‑24 months. Late stones (>5 years) are less common.
• Recipient gallbladder: If the recipient still has a gallbladder at transplant (common in non‑biliary cirrhosis), stones may be pre‑existing or de novo.
• Donor bile duct stones: Rare but can occur from donor gallstones, biliary sludge, or stricture formation.

Why are liver transplant recipients at risk?

Several post‑transplant factors promote gallstone formation:

• Biliary strictures (anastomotic or non‑anastomotic): Cause bile stasis, a major lithogenic factor. Strictures occur in 5‑15% of transplants.
• Immunosuppressants: Calcineurin inhibitors (tacrolimus, cyclosporine) alter bile composition and reduce gallbladder motility. Sirolimus may increase cholesterol saturation.
• Denervation of the graft: The transplanted liver lacks neural input, impairing gallbladder contraction and sphincter of Oddi function.
• Ischemia‑reperfusion injury: Damages bile duct epithelium, leading to sludge and stone formation (ischemic cholangiopathy).
• Infection (e.g., CMV, recurrent hepatitis C): Can cause cholangitis and biliary debris.
• Prolonged fasting or TPN: Common in peri‑transplant period, leading to biliary sludge.

Clinical presentation – mimicking rejection or infection

Symptoms of gallstones in liver transplant recipients can be subtle or atypical due to immunosuppression and denervation.

• Asymptomatic: Up to 50% of stones are discovered incidentally on routine imaging.
• Biliary colic: Right upper quadrant pain – but may be absent due to denervation.
• Cholangitis: Fever, jaundice, RUQ pain – must be differentiated from acute rejection or viral hepatitis. Cholangitis is a medical emergency.
• Obstructive jaundice: Elevated bilirubin, alkaline phosphatase, GGT.
• Pancreatitis: If stone migrates into ampulla (rare but possible).

Because immunosuppression blunts inflammation, patients may present with sepsis without localising signs. A high index of suspicion is required.

Diagnosis: ultrasound, MRCP, EUS, ERCP

Imaging in transplant patients follows a stepwise approach:

• Transabdominal ultrasound: First‑line. Detects gallstones, sludge, biliary dilatation, and pericholecystic fluid. Limited in detecting intrahepatic stones or non‑dilated strictures.
• MRCP (magnetic resonance cholangiopancreatography): Excellent for biliary anatomy, strictures, and intrahepatic stones. Non‑invasive and avoids contrast nephropathy.
• EUS (endoscopic ultrasound): High sensitivity for choledocholithiasis, especially in non‑dilated ducts. Can also sample biliary strictures.
• ERCP (endoscopic retrograde cholangiopancreatography): Gold standard for diagnosis and treatment. Allows stone extraction, sphincterotomy, balloon dilation, and stenting. Carries risk of post‑ERCP pancreatitis (higher in transplant patients? – controversial).

In many centres, MRCP is performed first; if stones or strictures are found, ERCP is done for therapy.

Management: ERCP first, surgery high risk

Treatment depends on stone location and symptoms:

• Asymptomatic stones in native gallbladder: Observation is reasonable. Prophylactic cholecystectomy is debated (see below).
• Symptomatic gallbladder stones (cholecystitis): Laparoscopic cholecystectomy is high‑risk in transplant patients (immunosuppression, adhesions, portal hypertension). Non‑surgical options: percutaneous cholecystostomy, antibiotics, or ERCP if CBD stones present. Surgery reserved for failed medical management or complications.
• Common bile duct stones (choledocholithiasis): ERCP with sphincterotomy and stone extraction is first‑line. Success rate >90%. If duct is large, balloon dilation or mechanical lithotripsy may be needed. Post‑ERCP stenting if stricture present.
• Intrahepatic stones: Difficult to treat. ERCP with balloon sweeping into extrahepatic duct; if failed, PTC (percutaneous transhepatic cholangiography) with stone removal or lithotripsy.
• Recurrent stones: May indicate underlying stricture or biliary dyskinesia. Long‑term UDCA and endoscopic surveillance.

Surgical cholecystectomy considerations: Mortality rate 2‑5% (higher than non‑transplant). Morbidity includes bleeding (portal hypertension), wound infection, and bile leak. If surgery is unavoidable, perform in a high‑volume centre with transplant surgery backup.

Prevention: UDCA and prophylactic cholecystectomy

Preventive strategies are controversial but include:

• Ursodeoxycholic acid (UDCA): Several studies show that UDCA (10‑15 mg/kg/day) reduces biliary sludge and cholesterol stone formation after liver transplant. A meta‑analysis (2022) found a 60% relative risk reduction for gallstones. Many centres routinely prescribe UDCA for the first 6‑12 months post‑transplant, especially in patients with biliary strictures or prolonged TPN.
• Prophylactic cholecystectomy at time of transplant: Some centres remove the recipient’s gallbladder during OLT (if not contraindicated by portal hypertension or coagulopathy). This eliminates future gallbladder stones but adds operative time and risk. No randomised trial; retrospective studies show reduced biliary complications but increased operative time. Not standard.
• Donor gallstones: If the donor gallbladder contains stones, it is typically removed during back‑table preparation (donor cholecystectomy) to prevent post‑transplant stone‑related complications.
• Optimise biliary anastomosis: A wide, tension‑free duct‑to‑duct anastomosis reduces stricture and stone risk.

Current practice at most large transplant centres: UDCA for 6 months post‑transplant; routine cholecystectomy not performed unless donor stones or recipient has pre‑existing symptomatic stones.

Special issue: gallstones in the donor liver

Donor gallstones present a unique challenge:

• Prevalence: 5‑10% of deceased donors have incidental gallstones.
• Management during back‑table preparation: Surgeon palpates gallbladder; if stones are present, a donor cholecystectomy is performed. Stones within the donor bile ducts are rare but require duct exploration.
• If stones are missed: They can cause post‑transplant biliary obstruction, cholangitis, or pancreatitis. Some centres routinely perform intraoperative cholangiography on the donor liver before implantation.
• Living donor: Donors are screened for gallstones pre‑operatively; if found, the donation is typically cancelled or the donor undergoes cholecystectomy before donation (if time allows).

Donor‑transmitted gallstones are a preventable complication with careful back‑table inspection.

Interactive FAQ – Liver transplant and gallstones

Disclaimer: This information is for educational purposes. Management of gallstones in liver transplant recipients is complex and requires multidisciplinary care (hepatology, transplant surgery, advanced endoscopy). Consult a specialist at Vivekananda Hospital.